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Idiotype (Id) is an excellent tumor-specific marker for those tumor cells that
synthesize and display immunoglobulin (Ig) on their surface (1, 2) . Because a
given clone of B cells is committed to producing only one Ig species, surface Id
is shared by members of the tumor cell population but not by normal cells. We
and others have developed murine antiidiotype mAb to study the biology of
these diseases, and these reagents have shown some success in the treatment of
patients with B cell malignancies (3-6) .
However, patients have been recently described whose tumors have developed
variant Id proteins spontaneously over time or in response to treatment with
mAb (7, 8) .A major mechanism of such variation appears to be somatic mutation
in genes coding for the variable region of the expressed Ig molecule (9) . The
discovery of such variant forms of Id raises many issues related to tumor biology
and to the potential therapeutic application of mAb. For example, what is the
incidence and degree of Id diversity that could occur in B cell tumors? What is
the role of potentially mutagenic agents such as chemotherapy and irradiation
in generating Id diversity? It is important to define further the natural history
of this process by examining tumor populations in vivo over time and, ultimately,
to dissect the molecular mechanism responsible for such diversity . In this article
we report recent work from our laboratory that examined some of the issues
raised by our earlier studies and we describe an approach whereby clonal isolates
of the tumor population and their Ig protein products can be obtained and
separately analyzed .
Materials and Methods
Patients
Case 1 . A 42-yr-old female developed generalized lymphadenopathy after a 1-yr
history of lymphocytosis . Bone marrow biopsy results revealed gross lymphomatous
involvement and biopsy findings of a right inguinal lymph node were consistent with
nodular mixed lymphocytic and histiocytic lymphoma . The clinical stage was IVA . A
separate biopsy was performed to obtain tissue for mAb production . No therapy was
instituted . Over the next year she experienced spontaneous regression of her disease with
resolution of cervical and supraclavicular, lymphadenopathy, although moderate inguinal
adenopathy remained . Repeat inguinal lymph node biopsies were performed I yr after
referral and revealed persistent disease . During the ensuing year disease progressed in
multiple lymphatic sites, requiringchemotherapy .
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Case 2.
￿
A 50-yr-old female had an epigastric mass, discoveredon routine examination.
An exploratory laparotomy was performed and a large mesenteric mass was biopsied and
disclosed nodular lymphoma, poorly differentiated, clinical stage IIA. Treatment was
initiated with chlorambucil and a complete tumor response occurred. This medication
was stopped after a total of 1 yr. Four months later, left inguinal adenopathy was noted
and a biopsy again showed nodular, poorly differentiated lymphoma. Over the next year,
bilateral inguinofemoral adenopathy developed and moderately prominent retroperito-
neal nodes were detected by computed tomography scanning. Chemotherapy was reinsti-
tuted with cyclophosphamide, vincristine, and prednisone, which induced a partial tumor
regression . A repeat biopsy was performed and tumor cells were obtained for mAb
development. Symptomatic inguinofemoral adenopathy was treated with radiation ther-
apy, although it did not resolve completely. During the following year, cervical, axillary,
and epithochlear adenopathy developed, and a repeat biopsy of an axillary node was
performed. A subsequentremission was induced by several months ofcombination therapy
consisting of cyclophosphamide, vincristine, procarbazine, and prednisone.
Human Malignant Cells
Tumor samples were minced, passed through a sterile seive, and washed in complete
media containing RPMI 1640 (Irvine Scientific, Woodland, CA), with 12% FCS supple-
mented with 100 U/ml penicillin, 100 ug/ml streptomycin, and 2 mM glutamine (Gibco,
Grand Island, NY). Samples were frozen in 90% FCS/10% DMSO in liquid nitrogen.
After thawing, cells were washed in complete media, and viable mononuclear cells were
isolated by sedimentation on a Ficol-Hypaque gradient.
Recovery of Tumor Idiotype
Idiotype was recovered by "rescue fusion" from tumor cells by methods described
previously (10, 11). Briefly, tumor cells were fused with K6H6/B5 a mouse human hybrid
myeloma cell which is a nonsecretor of Ig. Hybrids were screened for the production of
human Ig by an ELISA. Plastic microtiter plates (Immulon 2, Dynatech Diagnostics, Inc.,
South Windham, ME) were coated with goat anti-human Ig antibody (Tago Inc., Burlin-
game, CA) at a concentration of I0 jug/ml . Plates were washed with 0.15 M NaCl, 0.05%
Triton X-100. 30 ,ul of supernatant from wells with hybrids was then added and incubated
for 1 h at room temperature (RT).' The plates were washed and human Ig was detected
with goat anti-human U, K, and X antibodies labeled with horseradish peroxidase (HRP)
(Tago Inc.) diluted in PBS with 0.1 % BSA. Plates were again incubated at RT for 1 h,
and enzyme substrate 2,2-azino-di(3-ethylbenzthiazoline sulfonic acid) 150 Ag/ml (Sigma
Chemical Co., St. Louis, MO) in 0 .05 M citrate buffer, pH 4 .0, with 0.0045% hydrogen
peroxide was added. Color development was measured by an ELISA spectrophotometer
at a wavelength of 405 nm (automated micro-ELISA reader, Dynatech Diagnostics, Inc.).
Wells with values >20% of positive control (purified human paraprotein 500 ng/well)
after subtraction of background were scored as positive.
Wells with the most positive signals were expanded and cloned by limiting dilution
using irradiated BALB/c mouse spleen cells as a feeder layer.
Anti-Id Antibodies
Idiotype protein was isolated from culture supernatant by affinity chromatography
using goat anti-humanA antibody (Tago Inc.) coupled to a CNBr-activated Sepharose 4B
affinity column (Pharmacia Fine Chemicals, Piscataway, NJ). BALB/c mice were immu-
nized i.p. with 50,ug of purified protein in CFA, received a booster 7 d later, and another
dose intravenously on day 14. Spleens were removed on day 17 and were fused to P3 x
63 Ag 8 .653, a nonsecreting mouse myeloma line, by standard techniques (12). Hybrids
were screened for reactivity with purified protein by an ELISA. Id was used to coat
microtiter plates (10 ug/ml). Plates were washed and 30-50 U1 of culture supernatant
from wells with hybrids was added. Plates were incubated for 1 h at RT and were again
washed. Purified goat anti-mouse Ig coupled to HRP was then added and incubated for
' Abbreviations used in this paper:
￿
HRP, horseradish peroxidase; RT, room temperature.
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1 h . Afterwashing, substrate was added and color development was measured by methods
described above. Positive control consisted of culture supernatant from a hybrid-secreting
antibody specific for human A constant region (1 D12) and the negative control was a mAb
specific for Id from an unrelated B cell lymphoma.
In order to detect antibodies directed against Ig idiotypic determinants, hybrids that
demonstrated reactivity by the above assay were then screened by ELISA on a panel of
three Ig proteins from unrelated B cell tumors. Antibodies that retained their specificity
were used to stain frozen tissue sections of the patient's original lymphoma by the
immunoperoxidase technique (13). Specificity was again checked by staining normal
human tonsil. Finally, antibodies were also screened for binding to whole tumor cells from
the original tumor by indirect immunofluorescence. An affinity-purified goat anti-mouse
Ig reagent coupled to FITC (Becton, Dickinson & Co., Mountain View, CA) was used as
a second step. Surface immunoglobulin was detected by direct immunofluorescence using
affinity-purified FITC-conjugated antibodies specific for A, K, and X chains (Becton,
Dickinson & Co.) or by indirect immunofluorescence using a mouse monoclonal antibody
specific for the A constant region (ID12) followed by the FITC-labeled anti-mouse
reagent. T cells were detected by staining with FITC-conjugated human anti-Leu-4 mAb
(Becton, Dickinson & Co.). All fluorescence analysis was performed with a fluorescence-
activated cell sorter (FACS IV, Becton, Dickinson & Co.).
Competitive Inhibition Assays
Purified Id (case 1) was used to coat flexible microtiter plates (Becton, Dickinson & Co.)
at a concentration of 10 wg/ml at 4°C overnight. Anti-Id antibodies were purified from
supernatent over a CNBr-activated Sepharose 4B column (Pharmacia Fine Chemicals) to
which a goat anti-mouse antibody (Tago Inc.) had been coupled. Antibodies were
iodinated with ' z'I by the chloramine T method (14) . Plates were washed and blocked
with 2.0% nonfat dry milk in PBS for 45 min at RT. After rewashing, 50 ml of anti-Id
mAb supernatant was added and incubated at RT for 1 h. All supernatants were adjusted
with complete media to the concentration present in the lowest secretor (1 .5 wg/ml). "'I-
labeled antibody was then added and incubated for an additional 30 min. Plates were
washed and dried, and individual wells were counted. Each antibody was tested for its
ability to block itself and the four other mAb. Maximum binding was assessed by using
an irrelevant mAb directed against Id from an unrelated B cell tumor as a first step. Each
assay was done in quadruplicate and percent inhibition was defined as % inhibition
= 100 x (1 - experimental cpm)/(maximum cpm).
Analysis ofId-producing Hybrids with Anti-Id Antibodies
Rescue hybrids from case 1 that secreted intact Ig were tested further for their reactivity
with a panel of anti-Id mAb . A four-step ELISA assay was used: goat anti-human Ig,
culture supernatant, anti-Id supernatant, and goat anti-mouse Ig (Tago Inc.). Positive
control again consisted of a mouse anti-human u reagent (1 D12) and negative control
consisted of supernatant alone. Wells with signals at least 0 .100 OD units above control
after subtraction of background were scored as positive.
Southern Blot Analysis ofRearranged Ig Genes
DNA was isolated from whole tumor samples, the myeloma parent line K6H6/B5, and
Id-producing rescue hybrids. 10 ug of DNA was digested with the appropriate restriction
enzyme (New England Biolabs, Beverly, MA) overnight at 37 °C, and samples were then
electrophoresed on a 0.8% agarose gel. DNA was transferred to an activated nylon filter
(Genatran 45, Plasco Inc., Woburn, MA), and filters were probed with "P-labeledgenomic
sequences homologous to the JH and Cu regions of the heavy chain and to Ca regions of
the light chain by methods described previously (11, 15, 16) . The heavy-chain probes
were a 6 .5 kb Bam HI-Hind III fragment, which includes the germline JH region and a
1 .2 kb Eco RI fragment, which spans the first, second, and a portion of the third exon of
the Cu gene (17) . A combined C,, probe consisting of a 2.5 and a 3.5 kb Eco RI-Hind III
fragment was also used (18). Phage X DNA digested with Hind III was run in parallel as
a molecular size standard.CARROLL ET AL.
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Results
Analysis of Tumor with Anti-Id Antibodies.
￿
One idiotype protein that was the
product of a cloned rescue hybrid from each patient's tumor was purified, and
five independent anti-Id mAb were generated foreach patient. These were used
to analyze tumor samples by immunoperoxidase on tissue sections, and by
immunofluorescence on cell suspensions. Results oftissue section staining from
both patients showed that different portions of tumor were recognized by
individual mAb (Fig. 1). Certain mAb seemed to recognize all of the tumor cells
defined by surface M staining, whereas others bound to smaller subsets of cells.
Populations oftumor stained by individual mAb were overlappingandnottotally
distinct from one another.
In order to quantitate this phenomenon better, FACS analysis of tumor cell
suspensions was performed. Table I shows staining ofbiopsy material from both
cases taken at the time of referral and another sample harvested 1 yr later.
Samples were analyzed for T cell infiltration using anti-Leu-4, and total tumor
was again estimated by surface A staining or by subtracting the percentage of
cells stained for the irrelevant light chain from those bearing the light chain
associated with tumor (A - ic). The five mAbwereagain tested for their reactivity
with the tumor. It is apparent that these antibodies recognized subpopulations
of total tumor and that no single mAb stained the total tumor, although a few
bound the majority ofcells (case 1, 2G8, 4134; case 2, 5133). However, a mixture
of all five antibodies captured total tumor in some instances (case 1, 1983; case
2, 1983). The small difference between the percentage of tumor cells detected
by the mixture of antibodies in case 2 one year after referral might represent
infiltration with normal B cells. Alternatively, it is possible that an increasing
number of Id variants had evolved during the year.
The percentage oftumor recognized by a single antibody could differ between
tumor samples taken from different anatomical locations. For example, antibody
31`2 recognized 16% of cells taken from one inguinal lymph node in patient 1
and captured twice as many, 34%, when analyzed on tumor taken from an
adjacent lymph node sampled at the same time. Percent total tumor was similar
in both lymph nodes. In addition, these percentages could change over time.
Antibody 1D9 recognized 38% of cells from a lymph node from patient 2 at
referral and 62% of the cells were stained 1 yr later.
Because a single cloned rescue hybrid was used as a source of Id protein to
create anti-ld antibodies in both these cases, it would appear that each anti-ld
recognized a distinct antigenic site (idiotope) on the variable region of the
molecule . These idiotopes were variably shared by the Ig molecules produced
by the tumor population .
Competitive Binding Assays.
￿
Competitive binding assays were performed to
prove that individual anti-Id antibodies recognized different idiotopes as pre-
dicted by the staining data. These results summarized in Table 11 show that no
two mAb share an identical blocking pattern. In addition, the data suggest that
these idiotopesare closelyrelated spatially, in that thebinding ofasingle antibody
(4134) blocks targeting ofall the other anti-Id mAb.
Recovery of Individual Id Variants.
￿
Extensive analysis of individual hybrids
from case 1 was carried out in order to sort individual Id variants from a
heterogeneous tumor sample . Each hybrid would be expected to secrete a single1570
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Case 1
Case 2
* Values are percentage of total sample stained by FRCS analysis.
TABLE II
Competitive Binding to Id by Anti-Id Antibodies
idiotype species. The fusion was initially screened for heavy- and light-chain
secretion, and those hybrids that secreted complete Ig were then screened with
four of the five anti-Id antibodies. Mathematically, a total of 16 different patterns
could be recovered if each antibody recognized a distinct epitope and if a
representative of each of the possible combinations existed in the panel of rescue
proteins. In fact, I1 different reactivity patterns were observed (Table III).
Those not seen would be expected to be present in low frequency based on the
percentage of total tumor sample stained by individual mAb (Table I). For
example, patterns lacking binding with antibodies 4D4 and 2G8 should be rare
because these antibodies reacted with a major portion of the tumor cell popula-
tion . Strict statistical correlation is confounded somewhat by thepossible presence
of more than one hybrid per well, inasmuch as supernatants were tested without
prior subcloning. 13% of the hybrids produced an Ig product that did not react
with any of the four anti-Id antibodies. It is possible that these represent the
products of normal B cells within the biopsy specimen. Alternatively, they could
FIGURE 1 .
￿
(A) Lymph node biopsy obtained from case 1 at presentation. Tissue is stained
with mAb by the immunoperoxidase technique. Total tumor is recognized by staining with
anti-,u reagent (upper left). Three different anti-Id antibodies were then used to stain the same
area and this is seen on the suceeding three panels. Anti-Id mAb recognized subpopulations
oftotaltumor. Antibodies 2G8and 4D4 sawa majorportion oftumorwhereas6H9recognized
a smaller fraction. (B) Lymph node biopsy from case 2 at referral. Total tumor is again
approximated by surface k staining (upper left). Three anti-Id mAb stained varying portions
of total tumor. Antibody 1D9 (upper right) seemed to stain total tumor when compared to
anti-R staining (upper left). Anti-Id mAb 6911 and 2H10 recognized much smaller fractions.
TABLE
Anti-Id Antibodies Recognize
I
Tumor Subpopulations
Date
Sample
Site
T cell
Leu-4
Ig
3C10 6H9
Anti-Id
4D4 2G8 3F2 Mix
1983 Inguinal 13* 75 31 48 45 63 23 76
1984a Inguinal 33 60 20 35 ND 45 16 54
1984b Inguinal 33 65 29 43 ND 54 34 52
Leu-4 X - K 5D3 6D11 2H10 1D2 1D9 Mix
1983 Inguinal 25 75 60 11 16 11 36 71
1984 Epitrochlear 19 69 61 20 14 5 62 58
125I-labeled
antibodies
Percent
4D4
inhibition
3F2
by unlabeledantibodies
6H9 3C10 2G8
4D4 81 46 66 31 65
3F2 80 77 10 0 73
6H9 62 0 92 45 6
3C10 73 0 76 52 62
2G8 82 60 14 57 93CARROLL ET AL.
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TABLE III
Recovery ofId Variantsfrom Heterogeneous TumorPopulation
* +, reactivity with anti-Id mAb; -, nonreactivity with mAb.
represent tumor variants lacking idiotopes detected by these particular anti-Id
antibodies.
Southern Blot Analysis of Ig Genes.
￿
The genetic mechanism responsible for
such diversity was explored using Southern blot analysis of rearranged Ig genes
on DNA obtained from biopsy material and from two hybrids from case 1, each
producing an Ig product with a different pattern of reactivity with anti-Id
antibodies. The analysis was also performed on the parental myeloma fusion
partner used to create these hybrids, because it carriesanonfunctional rearrange-
ment for the heavy chain (11). Using Eco RI-digested material from biopsy
material, two heavy-chain rearrangements were detected using a JH probe (Fig.
2A): one larger (20.1 kb) and one smaller (10.2 kb) than the germline band
(represented by the arrow). The active allele is the lower 10.2-kb band (repre-
sented by the arrowhead) because it is the only rearrangement seen in Id-
secreting hybrid 2 (11). The K6H6/B5 myeloma parent had one rearranged
band, and this was retained by hybrid 1 (-+++). In addition, this hybrid
demonstrated two smaller rearrangements not seen in the analysis of biopsy
material . In contrast, hybrid 2 (--++) contained a single band, which was
identical to the lowerrearrangement seen in tumor tissue. The two smaller bands
in hybrid 1, when added together, approximated the size of the active rearrange-
ment seen in the biopsy and in hybrid 2. Therefore, it appears that an Eco RI
site had been created in theJH region in the active heavy chain allele retained in
hybrid 1 (-+++).
In order to analyze further the diversity seen in the heavy-chain gene, a
different enzyme, Bam HI, was used to digest DNA samples and a different
probe Qu, a 1.2-kb germline sequence that hybridizes to aportion of the constant
region of the heavy chain was used. Tumor tissue was analyzed previously (data
not shown) and the location of the productive rearrangement seen in biopsy
Predicted
patterns 3C10
Anti-Id antibodies
6H9 4134
wells
2G8 positive (n)
Percent
positive
1 +* + + + 158 46
2 - - - + 71 20.9
3 - - - - 44 13.0
4 - - + + 32 9.4
5 + - + + 11 3.2
6 - - + - 9 2.7
7 - + + + 4 1.2
8 + + - + 3 0.88
9 + - + - 3 0.88
10 + + + - 3 0.88
11 - + - + 1 0.30
12 + - - + 0 -
13 + - - - 0 -
14 + + - - 0 -
15 - + + - 0 -
16 - + - - 0 -
Total: 3391574
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FIGURE 2 .
￿
Southern blot analysis of rearranged Ig genes . TumorDNA was obtained from a
lymph node biopsy taken from case 1 at diagnosis . DNA was also harvested from two rescue
hybrids generated from a fusion between tumor (also obtained from case 1 at diagnosis) and
K6H6/B5 a nonsecreting mouse human heteromyeloma cell line . The Id protein secreted by
each of these hybrids demonstrated a different pattern of reactivity with four of five anti-Id
mAb (Table III) . Hybrid 1 Id was recognized by three of four mAb (-+++), while hybrid 2
wasbound by two(--++) . DNA from the myeloma fusion partnerwas also run for comparison
because it is known to contain a nonfunctional rearrangement (11) . Twoprobes were used to
identify heavy-chain sequences : a 6.5-kb Bam HI/Hind III sequence which includes the entire
JH germline region, and a 1 .2 kb Eco RI Cju probe which spans the first, second, and a portion
of the third exon of the CjA germline sequence (17) . Two germline sequences were combined
and used to detect light-chain rearrangements, a 2 .5-kb Eco RI-Hind III fragment, which
includes the Mcg C,, sequence and a 3.5-kb Eco RI-Hind III fragment containing the Ke-
Oz-Ca gene . DNA from normal granulocytes was used to identify germline sequences and
these are indicated by arrows . Molecularweight standardscorresponding to Hind III-digested
phage a DNA are also indicated . (A) Eco RI digestion, JH probe . Two rearrangements were
seen with biopsy material (20.1 and 10 .2 kb). The active rearrangement is the lower 10.2-kb
fragment in that it is the only rearrangement retained by Id-secreting hybrid 2 (11) and this
is identified by an arrowhead . In addition, a third larger band is seen and this represents a
partially digested fragment because it was not seen on multiple blots done previously using
the same sample, enzyme digestion, and probe . The K6H6/B5 myeloma parent contains a
band and this was retained in hybrid 1 . Hybrid 2 retained a band that is identical to the active
rearrangement seen with biopsy material . However, hybrid I demonstrated two smaller
fragments whose size when addedtogether approximated the size of the active rearrangement .
(B) Bam HI digestion, Cu probe . Biopsy material was run previously (data not shown) and the
location of the active rearrangement is indicated by the arrowhead (11). The myeloma parent
again demonstrated a single nonproductive rearrangement and this was again seen in hybrid
1 . Hybrid 1 also contained a 10 .9-kb rearrangement while hybrid 2 showed the same 9.5-kb
band seen in biopsy material . Thus, Southern blot analysis with two differentenzyme digestions
(combined with two heavy-chain gene probes) demonstrated different restriction patterns in
the rearranged genes coding for Id proteins with differential staining by a panel of anti-Id
mAb. (C) Analysis of light-chain rearrangements using Eco RI digestion and CA probe . Three
germline bandswere seen in biopsy material and a larger 22 .8-kb band was also seen in tumor
and control DNA . An identical 6.0-kb rearrangement was seen in the tumor tissue and both
hybrids . Therefore, in contrast to differences in heavy-chain sequences both hybrids have
identical light-chain rearrangements .
material is indicated by the triangle seen in Fig. 2B (11) . Again, hybrid 2 shared
an identical 9.4-kb rearrangement with that seen in biopsy material and a
dissimilar larger (10.9 kb) rearrangement was seen in hybrid 1 . This suggests
that a Bam HI site had been lost within the gene coding for this Id variant .
Again, the myeloma parent contained a nonfunctional rearrangement and this
is represented by a band in hybrid 1 .
In contrast to the diversity seen in analysis of heavy-chain genes, the X light
chains, within the limits of analysis using a single enzyme and single probe, wereCARROLL ET AL.
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identical. Three germline bands are seen in the biopsy sample (Fig. 2C) and a
larger (23 kb) band was also present in both tumor and control DNA. This most
likely represents a restriction site polymorphism known to be associated with the
lower germline band. (19) One 6.0-kb, representing the active rearrangement,
is seen in biopsy material and this is shared by both hybrids.
Discussion
Most human lymphoid neoplasms are of B cell lineage, and these diseases
mirror various stages of normal B cell development (20). Because each B cell is
programmed to produce only one antibody species, those malignancies that
express surface Ig provide an opportunity to specifically mark tumor cells with
tailor-made antibodies. We have used anti-Id antibodies to study tumor biology
in this group of diseases and have explored their therapeutic use (3, 5, 6, 12).
Indeed, these reagentshave shown promise in clinical trials, with 50% ofpatients
achieving a clinically significant response (6). Although one sustained complete
clinical remission has been achieved, most of these responses have been short in
duration, with eventual regrowth of tumor.
One potential mechanism of tumor escape is through the development of Id
variants within the tumor population that cease to bind antibody. Ifthe effects
of antibody were powerful, and if subpopulations of Id variants existed within
the tumor population, then treatment with a single mAb would be expected to
provide a strong selective advantage to the variants not sharing the antibody-
binding site (idiotope) recognized by that mAb. Recently, we have observed this
exact occurrence (7).
The mechanisms responsible for the enormous antibody diversity achieved by
the immune system are better understood. A series of germline DNA segments,
three for the heavy chain (V, D, J) and two for the light chain (V, J), rearrange
to form one functional coding sequence for the variable region of each Ig chain
(21-23). Combinational possibilities owing to the selection ofone out ofseveral
hundred V segments with one ofa series ofD segments (heavy chain) and a small
number ofJ segments result in enormous diversity. In addition, the exact site at
which these different regions combine is imprecise, and nucleotides may be
added at the D segment boundaries, thus amplifying the process still further
(24-27). Finally, pairing ofdifferent light and heavy chains accounts for another
level of antibody diversity.
In addition to the above mechanisms, it is now generally accepted that point
mutations within the rearranged variable region encoding sequences serve to
expand enormously the antibody repertoire, especially during the primary im-
mune response (28-30). Indeed, the role of somatic mutation in active Ig V
region genes of normal B cells has been estimated to be 10-s per base pair per
cell division (31). Most of this information on somatic mutation comes from the
study of murine myelomas and hybridomas with a restricted antibody response
against simple haptens, and little information is available regarding the role of
somatic mutation in the human immuneresponse. In that B cell tumors represent
stages ofnormal B cell development, they may be expected to undergo some of
the processes leading to antibody diversity seen in the normal immune response.
We have previously described cases of antibody (1d) diversity within B cell
tumors whereby subclones emerged over time or after treatment with mAb and1576
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did not bind the single mAb (7). In these cases Id' and Id- populations shared
identical Ig gene rearrangements, and the changes appeared to be the result of
point mutation within common rearranged V(D)J sequences. This allowed for a
structural change in the idiotope recognized by the anti-Id antibody (7). We have
recently documented the role of somatic mutation in generating Id diversity at
the nucleic level in one of these cases (9).
In this paper we report that striking variations of Id structure may exist at the
time of diagnosis in patients with B cell tumors. This extreme diversity was
documented by the differential staining of tumor by a panel of anti-Id mAb in
both tissue sections and by FACS analysis. Crossblocking studies confirmed that
antibodies were directed against different idiotopes on the Ig molecule . In one
case, individual variant Id proteins were recovered after fusing tumor tissue with
a nonsecreting heteromyeloma line. If each of the resulting hybrids secreted a
single species of Id, and the four mAb recognized different Id determinants,
then 16 different patterns should emerge. I1 of 16 patterns were actually
observed, and the five patterns not observed would be expected to be infrequent.
Thus, it appears as though the Id variants secreted by these hybrids mirrors
their representation within the original tumor.
These studies also demonstrate that diversity can occur prior to the institution
of potentially mutagenic therapy such as chemotherapy or irradiation, although
it is possible that such exposure would amplify the apparent high rate of somatic
mutation .
In order to generate the panels of mAb described in this report, a single Id
protein (from one cloned hybrid) was used as an immunogen, and five different
anti-Id mAb were generated. Each of these mAb reacted with a distinct but
sometimes overlapping subpopulation of tumor cells. It would appear then that
even though extensive tumor Id variation is seen in these cases, these proteins
are related with multiple idiotopes being shared by varying portions of the total
tumor population . Further evidence of a common origin is seen on Southern
blot analysis of rearranged Xgenes (case 1), where bands of identity are visualized
between tumor and both hybrids. Because these variants are related, it is likely
that somatic variation led to the development of multiple forms from a common
rearranged V(D)J precursor. Extensive somatic point mutation as occurs in
normal B cells would be the most likely genetic mechanism responsible for the
observed tumor variability.
Extensive somatic variation is also suggested by Southern blot analysis of
rearranged heavy-chain genes. Differences in restriction patterns were seen
between two hybrids derived from members of the same tumor clone. By using
two different probes (JH, CA), hybrid 2 (--++) revealed a band on two different
restriction digests (Bam HI, Eco RI) that was identical to that seen in analysis of
whole tumor. However, hybrid 1 (-+++) showed patterns that were consistent
with the loss of one restriction site (Bam HI) and the creation of another (Eco
RI). The Eco RI site was created within theJH region, which places this site of
mutation within the third hypervariable region of the V protein encoding
sequence. The size of the Bam HI restriction fragment (^-9.4 kb) would place
the site of mutation within the intron separating the variable and constant
portions of the Ig coding sequence (17). Thus mutations seem to be taking place
in coding and noncoding portions of these genes.CARROLL ET AL.
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We previously reported cases of tumor Id variations that were discovered
when few subclones evolved that lost the ability to bind a single mAb (7).
However, when these clones were analyzed at the nucleic acid level, multiple
variants with extensive nucleic acid substitutions were identified even before
mAb treatment (9). The extreme heterogeneity reported here may be due to
even more extensive changes in DNA sequence, or it may be attributed to our
ability to detect changes in protein structure more readily, in that multiple mAb
were targeted to different idiotopes. Genetic analysis correlating changes in
protein structure with nucleic acid substitutions is needed to clarify this issue.
The cases presented here are exceptional in our experience in that a large
number of variants were documented . However, it is noteworthy that subpopu-
lations defined by anti-Id antibodies were relatively stable over a long period of
time, suggesting that mutation may have occurred early in the evolution of the
malignant clone or that certain Id proteins had a selective advantage. In the case
previously reported, the somatic mutational process resulted in nonrandom
clustering of nucleicacid substitutions alongthe VH region (9). More specifically,
no changes were noted in CDR1 and CDR3, whereas CDR2 accumulated many
mutations, most of which resulted in amino acid substitution. Thus, endogenous
selective forces may be active to preserve certain regions while allowing others
to change. The nature of such forces is uncertain. Antigen-driven systems have
been well described in murine responses to simple haptens, whereby mutations
produce antibodies with increased affinity for antigen (30, 32-34). Despite the
degree of mutation that we have now seen in B cell tumors, there seems to be a
selection for functional Ig molecules. Alternatively, an Id network mediated by
either antibody or T cells may be operative.
One obvious question is why the multiple bands seen in hybrid 1 (-+++) were
not seen in samples of lymph node biopsies. Based on the percentage of tumor
stained by individual mAb (from Table I), the expected frequency of this variant
would be on the order of 5%, which would be below the level of detection on
these blots.
The recognition of dissimilar restriction patterns in analysis of the heavy-chain
genes from different but related variants suggests that Southern blot analysis
must be carefully interpreted if it is to be used to identify clonal relationships.
Multiple different enzyme and probe combinations are sometimes required, as
has been previously shown by others (35). We show here that multiple rearranged
bands (more than two) may actually represent extensive somatic mutation within
common V(D)J rearrangements rather than the existence of multiple clones
(subclones) with different germline V(D)J sequences.
The existence of multiple Id variants raises many issues concerning the
potential therapeutic usefulness of anti-Id mAb. It is clear that such mutation
occurs to a different degree in every patient, and this may reflect the different
stages of B cell differentiation represented by these tumors. In addition, our
previous experience in clinical trials indicates that mAb may apply a powerful
positive selective force, amplifying Id variants that were not recognized by the
mAb. A collection of anti-Id antibodies can clearly be generated that would be
targeted to different idiotopes shared by varying numbers of tumor cells. This
can be facilitated by using multiple Id proteins rather than the product of a
single cloned rescue hybrid as an immunogen to create anti-Id mAb. Further-1578
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more, mAb with more comprehensive tumor reactivity can be selected by
screening on multiple Id protein isolates from the tumor. Although an individual
Id variant may lose certain idiotopes through somatic mutation, it will retain
others that could still allow its detection by the appropriate mAb. It is encour-
aging to note that in these two cases a single randomly selected Id protein was
used to create a panel of mAb, which when pooled together reacted with a
majority of tumor, both at diagnosis and 1 yr later. Thus, even in these two cases
with striking Id variation (the most striking to date), the majority of tumor,
retained idiotypes recognized by mAb. Clinical trials using multiple anti-Id mAb
are currently underway .
Summary
Using isolated idiotype (Id) protein we generated panels of antibodies in two
patients with follicular lymphoma, one of whom had never received priorchemo-
or radiotherapy. Flow cytometry and frozen section tissue staining of tumor with
these monoclonal antibodies (mAb) revealed multiple subpopulations within each
tumor. Individual mAb stained between 7% and 83% of surface Ig+ cells in the
tumor samples. These subpopulations were overlapping and no single antibody
recognized all the tumor cells. However, combinations of antibodies seemed to
capture total tumor in both cases. In some instances, the percentage of tumor
stained by a single mAb varied over time, and differed between lymph nodes
sampled at the same time. Because a single species of Id protein was used to
generate mAb in each case, it appears that the antibodies were directed against
idiotopes variably shared by different populations within each tumor, and this
was confirmed by crossblocking studies. Tumor cells from one patient were
fused to a nonsecreting heteromyeloma line K6H6/B5, and most of the resulting
hybrids secreted Id protein. Four mAb were used to screen the Id proteins
secreted by these hybrids, and 11 different variants (16 maximal) were found.
Southern blot analysis of rearranged Ig genes was done in two hybrids and biopsy
material. Identically rearranged light-chain genes were seen but it appeared as
though extensive somatic variation had occurred in heavy chain genes.
These studies indicate that: (a) striking Id variation can exist at diagnosis in
untreated patients, (b) the percentage of tumor represented by an individual
variant may change with time and may differ between tumor sampled from
differentanatomical locations, and (c) somatic variation appears to be responsible
for the observed heterogeneity. Although this degree of variation makes anti-ld
antibody therapy more difficult, appropriate combinations of mAb should be
more efficacious than single antibodies in such cases.
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